MAPT and Alzheimer disease: Realizing this promise will depend on using proteomics-informed multi-omics to identify meaningful patient subtypes, refine diagnostics, and guide mechanism-based therapies, thereby moving beyond Aβ- and tau-centric views toward a more complete and clinically actionable model of AD.